Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

926 - Ganoderic acids BT-01, a galectin-1 inhibitor, suppresses ovarian cancer growth in humanized mouse xenograft model.


24 Nov 2018


Poster display - Cocktail


Translational Research

Tumour Site

Ovarian Cancer


Cheng-Po Huang


Annals of Oncology (2018) 29 (suppl_9): ix23-ix27. 10.1093/annonc/mdy430


C. Huang1, S. Chen1, H. Lai1, Y. Lin1, C. Su1, S. Wu1, C. Chang1, C. Tsao1, Y. Chen1, S. Wang1, Y. Liu1, S. Lin2, T. Chen1

Author affiliations

  • 1 Biomedical Institute, Trineo Biotechnology Co., LTD, 221 - New Taipei/TW
  • 2 Clinical Laboratory Sciences And Medical Biotechnology, National Taiwan University, Taipei/TW


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 926


Ovarian cancer is the leading cause of death from gynaecological malignancies. Galectin-1 has been implicated in cancer progression and metastasis, and associated with poor prognosis in ovarian cancer. It is evidence that galectin-1 participates in tumor progression by evoking T cell anergy and contribute to cancer-immune escape. Ganoderma lucidum has been reported to exhibit anticancer properties. BT-01, a ganoderic acid composition, was purified from Ganoderma lucidum consisting of ganoderic acids P, Q, T, S, R, Me and ganodermic acid S. In this study, the potential role of BT-01 on inhibition of galectin-1 expression and tumor growth in ovarian was investigated.


In vitro experiments were conducted to elucidate the effectiveness of BT-01 on galectin-1 expression, and in vivo studies were to evaluate the tumor growth and immune responses. The galectin-1 expression of ovarian cancer cells ES-2 treated with BT-01 was examined by real-time PCR and western blot. Peripheral blood mononuclear cells (PBMCs) isolated from healthy donors were injected intraperitoneally into mice to establish the humanized advanced immunodeficiency mice model (Hu-PBMCs-mice). Measurement of tumor volume was determined by CT imaging, expression levels of galectin-1 and T cell infiltration in tumor tissue were examined by immunohistochemical analysis.


A significant cytotoxic effect of BT-01 on ES-2 and its inhibition role on galectin-1 expression were detected in vitro. The tumor volume was decreased after treating with BT-01 in the immunodeficient mice, indicating the inhibition ability of BT-01 on tumor growth even with a defective immune system. Additionally, the tumor inhibition rate was increased in Hu-PBMCs-mice with BT-01 administration in comparison with non-humanized mice. Our findings suggested the tumor suppression effect of BT-01 which significantly decreased the expression level of galectin-1and enhanced T cell infiltration of tumor tissue in Hu-PBMCs-mice.


The study showed that BT-01, a potential galectin-1 inhibitors, suppressed the tumor growth and induced immune response to trigger synergistic effects for anti-cancer.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

λ Trineo Biotechnology Co., LTD.


λ Trineo Biotechnology Co., LTD.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.